CA-OPTRASCAN
OptraSCAN® , the leading On-Demand Digital Pathology solution provider, today unveiled a new Multi-Modality Digital Slide Scanner, with features such as high-speed, high-throughput, high-capacity and high-content, at the ongoing Pathology Visions 2018 conference in San Diego, CA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181105005212/en/
The scanner is fully equipped with confocal, epifluorescence and brightfield imaging modalities that are seamlessly integrated with OptraSCAN®’s proprietary Image Management and Advance IHC Multiplexing Image Analysis software. These cloud-enabled Multi-Modality Digital Slide Scanners are compact, as well as lightweight, and are available at a very competitive cost.
“Keeping with our motto of introducing most advanced and affordable digital pathology solutions, OptraSCAN has added one more feather in the cap with Multi-Modality Digital Slide Scanner’s addition to our technology-driven range of scanning systems. The high-resolution, high-contrast scanning images captured with this multi-modality scanner offers diagnostic capabilities beyond those of conventional microscopes or scanning systems,” said Abhi Gholap , Founder & CEO, OptraSCAN .
He further added, “It gives us immense pleasure to inform that The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) will be using our Multi-Modality Digital Slide Scanner for brain injury studies . This attests that this new range of scanners will help us expand to newer markets, and to address multiple needs of wide customer base from all segments.”
Key features of Multi-Modality Digital Slide Scanner :
- Delivers excellence in brightfield, fluorescent and confocal imaging
- Exceptional image quality for the most sophisticated multiplexing needs
- 20 color confocal, 30 color wide-field fluorescence and brightfield scanner
- High resolution multiplexed 3D imaging of thick tissue and 3D virtual slide production
- Autoloader for 1x3 and 2x3 inch slides with up to 300-slide capacity
-
Three synchronized high-speed filter wheels -
- Excitation, dichroic and emission can change channels in milliseconds
- Flexibility to adapt the scanning system to your requirements
- Supports Pixel-to-Pixel Spatial Registration for all imaged channels
- Automated on-the-fly spectral un-mixing of spectrally overlapping signals
- Seamlessly corrects any Vignetting and Photobleaching artifacts
- Cloud enabled & remote access with virtual slide viewer
About OptraSCAN, Inc.
OptraSCAN® (www.optrascan.com ) are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab's throughput or global location.
OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model. Follow Us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005212/en/
Contact:
OptraSCAN, Inc. Media Inquiries: Shruti Soman Manager – Marketing Communications 91.20.66540900 s.soman@optraventures.com or Sales Inquiries: Mike Oria Director of Sales – North America 415.407.9658 mike@optraventures.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom